Skip to main content
Erschienen in: Supportive Care in Cancer 5/2017

16.12.2016 | Original Article

Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy

verfasst von: Madhup Rastogi, Rohini Khurana, Swaroop Revannasiddaiah, Isha Jaiswal, Sambit S Nanda, Pooja Gupta, Kundan S Chufal, M L Bhatt

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy.

Methods

One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.

Results

Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05.

Conclusion

Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.
Literatur
2.
Zurück zum Zitat Nandakumar A (2016) Survival in head and neck cancers—results of a multi-institution study. Asian Pac J Cancer Prev 17(4):1745–1754CrossRefPubMed Nandakumar A (2016) Survival in head and neck cancers—results of a multi-institution study. Asian Pac J Cancer Prev 17(4):1745–1754CrossRefPubMed
3.
Zurück zum Zitat Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. RadiotherOncol J EurSocTherRadiolOncol 66(3):253–262 Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. RadiotherOncol J EurSocTherRadiolOncol 66(3):253–262
4.
Zurück zum Zitat Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J RadiatOncolBiol Phys 68(3):654–661 Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J RadiatOncolBiol Phys 68(3):654–661
5.
Zurück zum Zitat Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed
6.
Zurück zum Zitat McGuire DB, Correa MEP, Johnson J, Wienandts P (2006) The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer Off J MultinatlAssoc Support Care Cancer 14(6):541–547CrossRef McGuire DB, Correa MEP, Johnson J, Wienandts P (2006) The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer Off J MultinatlAssoc Support Care Cancer 14(6):541–547CrossRef
7.
Zurück zum Zitat Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Yeh S-A (2010) Radiotherapy for head and neck cancer. SeminPlast Surg 24(2):127–136 Yeh S-A (2010) Radiotherapy for head and neck cancer. SeminPlast Surg 24(2):127–136
11.
Zurück zum Zitat Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J RadiatOncolBiol Phys 68(4):1110–1120 Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J RadiatOncolBiol Phys 68(4):1110–1120
12.
Zurück zum Zitat Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed
13.
Zurück zum Zitat Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J RadiatOncolBiol Phys 16(6):1571–1575 Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J RadiatOncolBiol Phys 16(6):1571–1575
14.
Zurück zum Zitat Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92(4):875–885CrossRefPubMed Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92(4):875–885CrossRefPubMed
15.
Zurück zum Zitat Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl) 18(2):174–178CrossRef Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl) 18(2):174–178CrossRef
16.
Zurück zum Zitat Sheibani KM, Mafi AR, Moghaddam S, Taslimi F, Amiran A, Ameri A (2015) Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J ClinOncol 11(1):22–27CrossRef Sheibani KM, Mafi AR, Moghaddam S, Taslimi F, Amiran A, Ameri A (2015) Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J ClinOncol 11(1):22–27CrossRef
17.
Zurück zum Zitat Kamian S (2007) Benzydamine for prophylaxis of radiation induced oral mucositis in head and neck cancers: double-blind clinical trial. ASCO Meet Abstr 25(18_suppl):9042 Kamian S (2007) Benzydamine for prophylaxis of radiation induced oral mucositis in head and neck cancers: double-blind clinical trial. ASCO Meet Abstr 25(18_suppl):9042
18.
Zurück zum Zitat Kim JH, Chu FC, Lakshmi V, Houde R (1986) Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J ClinOncol 9(2):132–134CrossRef Kim JH, Chu FC, Lakshmi V, Houde R (1986) Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J ClinOncol 9(2):132–134CrossRef
Metadaten
Titel
Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy
verfasst von
Madhup Rastogi
Rohini Khurana
Swaroop Revannasiddaiah
Isha Jaiswal
Sambit S Nanda
Pooja Gupta
Kundan S Chufal
M L Bhatt
Publikationsdatum
16.12.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3548-9

Weitere Artikel der Ausgabe 5/2017

Supportive Care in Cancer 5/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.